

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>A61K 31/415</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 94/22441</b> <b>(43) International Publication Date:</b> 13 October 1994 (13.10.94)
<b>(21) International Application Number:</b> PCT/GB94/00650 <b>(22) International Filing Date:</b> 29 March 1994 (29.03.94) <b>(30) Priority Data:</b> 9306473.1 29 March 1993 (29.03.93) GB <b>(71) Applicant (for all designated States except US):</b> BIOGLAN IRELAND (R & D) LIMITED [IE/IE]; Unit 5, 151 Baldoyle Industrial Estate, Dublin 13 (IE). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> GOODMAN, Michael [GB/GB]; 27 Barley Rise, Baldock, Hertfordshire SG7 6RT (GB). FERGUSON, James [GB/GB]; Dept. of Dermatology, Ninewells Hospital, Dundee DD1 9SY (GB). <b>(74) Agent:</b> JUMP, Timothy, John, Simon; Venner, Shipley & Co., 20 Little Britain, London EC1A 7DH (GB).		<b>(81) Designated States:</b> AU, BB, BG, BR, BY, CA, CN, CZ, FL, GB, HU, JP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> USE OF CIS- OR TRANSUROCAMIC ACID FOR THE TREATMENT OF PHOTODERMATOSES AND IMMUNOGENIC SKIN DISEASES  <b>(57) Abstract</b>  A compound of the general formula (I): Q-R-X wherein Q is a substituted or unsubstituted furanyl, imidazolyl, pyrrolyl or thiopheneyl group, R is CR <sup>1</sup> <sub>2</sub> -CR <sup>2</sup> <sub>2</sub> , (cis)-CR <sup>1</sup> = CR <sup>2</sup> , or (trans)-CR <sup>1</sup> = CR <sup>2</sup> , X is COOR <sup>3</sup> or NR <sup>1</sup> R <sup>4</sup> , and R <sup>1</sup> -R <sup>4</sup> are each, independently, H, an alkyl or an aryl group and pharmaceutically acceptable salts thereof, are described for use in topical treatments of skin conditions which involve an overactive immune response, or which are responsive to UV irradiation. Pharmaceutical compositions of the compound of general formula (I) are also described.		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo			SE	Sweden
CH	Switzerland	KR	Republic of Korea	SI	Slovenia
CI	Côte d'Ivoire	KZ	Kazakhstan	SK	Slovakia
CM	Cameroon	LI	Liechtenstein	SN	Senegal
CN	China	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
CZ	Czech Republic	LV	Latvia	TJ	Tajikistan
DE	Germany	MC	Monaco	TT	Trinidad and Tobago
DK	Denmark	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali	UZ	Uzbekistan
FR	France	MN	Mongolia	VN	Viet Nam
GA	Gabon				

USE OF CIS-OR TRANSUROCANIC ACID FOR THE TREATMENT OF  
PHOTODERMATOSES AND IMMUNOGENIC SKIN DISEASES

## DESCRIPTION

5

The present invention relates to compounds of general formula I:-



10

wherein Q is a substituted or unsubstituted furanyl, imidazolyl, pyrrolyl or thiopheneyl group,

R is  $CR^1_2-CR^2_2$ , (cis) $CR^1 = CR^2$ , or (trans) $CR^1=CR^2$ , X is  $COOR^3$  or  $NR^1R^4$ , and  $R^1-R^4$  are each, independently, H, or

15 an alkyl or an aryl group and to pharmaceutically acceptable salts thereof. The invention also relates to the use of such compounds in the topical treatment of skin conditions considered to involve an over-active immune response, or which are responsive to ultraviolet (UV) radiation.

20

Trans-urocanic acid (UCA) is a naturally occurring compound found in the upper layers of the epidermis, where it is synthesized through deamination of histidine by histidase. When the skin is irradiated with ultraviolet  
25 light, up to 60 or 70% of the trans-UCA present is converted into the cis-isomer and it is thought that

- 2 -

cis-UCA, once so generated, functions as a mediator in both systemic and local UV induced immune system suppression. See the review article by M. Norval et al. in Photochemistry and Photobiology Vol. 50. No. 2, pp 267-  
5 275, 1989 (1).

Support for the proposition that cis-UCA is a mediator in UV induced suppression of the immune system is provided by the work reported by M. Norval et al. in  
10 Photochemistry and Photobiology Vol. 49. No. 5, pp 633-639, 1989 and that of V.E. Reeve et al., reported in Photodermatol Photoimmunol Photoreed 1991: 8: pp 176 - 180. The former authors found that cis-UCA was able to induce suppression of normal delayed type  
15 hypersensitivity response to herpes simplex virus type 1 in mice and the latter found that cis-UCA, generated by applying trans-UCA (in a cosmetic cream) to murine skin and then irradiating the treated skin, systemically suppressed normal contact hyper-  
20 sensitivity. Reeve et al. suggested that this activity is potentially harmful, since it could result in tumour development and, therefore, concluded that urocanic acid was potentially hazardous and should not be used as a cosmetic ingredient. Indeed, Reeve et al., in  
25 Photochemistry and Photobiology Vol. 49. No. 4. pp 459-464. 1989., reported that topically applied trans-UCA

- 3 -

significantly increased the tumour load induced in hairless mice, on exposure to Erythema inducing doses of UV light or sunlight.

5 Thus, rather than being confirmed as therapeutically useful, investigation of their metabolic roles has led to the removal of trans-UCA from various commercially available cosmetic creams (see Concar in the New Scientist, 16th May, 1992), to obviate the risk of it  
10 being transformed into the apparently harmful cis-isomer, and to cis-UCA being considered of potential use only in the treatment of serious or life-threatening conditions, such as those involving transplant surgery, etc. For example, cis-UCA has  
15 been suggested as a possible immuno-suppressive agent for use in transplant surgery, particularly in skin grafting.

However, contrary to the indications discussed above, it has now been found that certain UCA isomers,  
20 derivatives and analogues can be therapeutically useful. Accordingly, the present invention provides a compound of general formula I



25 wherein Q, R and X are as hereinbefore defined, or a pharmaceutically acceptable salt thereof, for use in a

- 4 -

topical treatment of a skin condition which involves an over active immune response or which is responsive to UV radiation.

5 In preferred embodiments of the invention, a compound of general formula (I) can be for use in a method of treating photodermatoses including polymorphic light eruption, photosensitivity, dermatitis/actinic reticuloid syndrome, actinic prurigo and solar  
10 urticaria; general urticarias of allergic and non-allergic type; contact sensitivity and skin diseases that respond to UV radiation including, acne vulgaris, alopecia areata, dermatitis herpetiformis, eosinophilic pustular folliculitis, erythrokeratoderma  
15 (symmetrical and progressive), chronic lichenoid GVH disease, granuloma annulare, histiocytosis X, ichthyosis linearis circumflexa, lichen planus, pityriasis lichenoides, pityriasis rosea, pityriasis rubra pilaris, pressure sores, pruritis (primary and  
20 secondary), scleromyxoedema, subcorneal pustular dermatoses, transient acantholytic dermatoses, psoriasis and atopic eczema. The invention, preferably, can relate to just one or a selection of the aforementioned conditions.

25

The invention further extends to a method of treating a skin

- 5 -

condition considered to involve an over active immune response, or a condition responsive to UV irradiation, inclusive of the specific conditions listed above, or just one or a selection of these conditions.

5

In a third aspect, the invention provides the use of a compound of general formula (I), as hereinbefore defined, for the manufacture of a medicament for use in the treatment of any one, a selection, or all of the  
10 conditions defined, or listed above.

In a further aspect, the present invention provides a pharmaceutical composition, comprising a compound of general formula (I), as hereinbefore defined, in  
15 admixture with a pharmaceutically acceptable excipient or carrier and suitable for topical use. Preferably, said composition is for use in treating a condition as hereinbefore defined or listed above.

20 In embodiments of any aspect of the invention, Q, in general formula (I), can be substituted with F, Cl, Br or -CH<sub>3</sub> but, preferably, is unsubstituted; R<sup>1</sup>-R<sup>4</sup> each, independently, can be H, a lower alkyl group (preferably C<sub>1</sub>-C<sub>4</sub>) or a phenyl group but, preferably, are H;  
25 and R, preferably, is (cis)CR<sup>1</sup>=CR<sup>2</sup>.

- 6 -

In all aspects and embodiments of the invention, the preferred compound general formula (I) is cis-UCA. However, the invention encompasses the topical application of trans-UCA and its conversion, in situ, to  
5 cis-UCA by irradiation with UV light. The necessary UV light can be provided from an artificial source or by exposure to sunlight. Preferably, the UV is provided using an artificial source.

10 Preferred pharmaceutical compositions, in accordance with the present invention, comprise ointments, gels, aerosols, wipes, creams, lotions or emulsions which include a compound of general formula I, in admixture with a suitable carrier, mixture of carriers or  
15 emulsion thereof.

Cis-UCA can be prepared from the trans-isomer which is available from Sigma UK Ltd. (Poole, Dorset, UK). To prepare the cis-isomer, a solution of trans-UCA at a  
20 concentration of 10mg/ml in dimethyl sulphoxide (or methanol) is spread thinly and irradiated under two Phillips TL20W/L UV lamps for three hours, which provide a total dose of 864 mj/cm<sup>2</sup> in the range 270-350 nm. The conversion rate of trans-UCA to cis-UCA is in the order of 70%.  
25 Thus, all compositions and preparations, in accordance with the invention, which include cis-UCA can also include



- 7 -

trans-UCA and, where quantities of cis-UCA are mentioned, a proportion thereof can be trans-UCA.

Methods of synthesizing other compounds of formula I are  
5 set out in M. Norval et al., Photochemistry and  
Photobiology Vol. 49. No. 5. pp 633-639. 1989.

Pharmaceutical compositions may be prepared by  
incorporating cis-UCA, prepared in the manner discussed  
10 above, into a conventional pharmaceutical cream or other  
suitable base, using conventional techniques known in the  
art.

The following examples are provided by way of  
15 illustrative embodiments and are not intended in any way to  
limit the scope of the invention.

#### Example 1

#### 20 Gel Composition.

100g of a gel composition, suitable for topical  
application to the skin, were prepared from the following  
quantities of the following substances:

25

cis-UCA

1.0g

- 8 -

Hydroxyethyl cellulose	2.0g
Nipasept Sodium	0.15g
Glycerol	10g
Water	to 100g.

5

The hydroxyethyl cellulose used was Cellosize QP52, OOH and was employed as a viscosity enhancer, as well as to provide the composition with the required gel characteristics.

10

The cis-UCA was prepared from trans-UCA by irradiating a thinly spread solution of 1.0g of trans-UCA, in dimethyl sulphoxide (10mg/ml), with two Phillips TL 20w/1 UV lamps for three hours. The conversion rate of trans-UCA to cis-UCA was approximately 70% and, therefore, the cis-UCA used contained up to about 30% trans-UCA. After irradiation, the remaining solvent was removed by evaporation and the cis-UCA was dissolved in a portion of the water. The remaining components were then mixed into the resulting solution and the rest of the water was added to form the final gel.

20

### Example 2

Cis-UCA, formed by the irradiation method set out in Example 1, was mixed into a jelly formed from 50% white soft

25

- 9 -

paraffin and 50% liquid paraffin at a concentration of about 2% w/w. The resulting composition was suitable for topical application to the skin.

5

**Example 3****Non-aqueous Spray.**

- 10 Non-aqueous sprays in accordance with the invention can be prepared using the following materials in the proportions set out below:

	% w/v
cis-UCA	0.1-5
15 isopropyl isostearate	10-40
cyclomethicone	10-40
Azone	0-20
oil (preferably coconut) to	100

- 20 The preferred composition for such a spray is 2% cis-UCA, 30% isopropyl isostearate, 30% cyclomethicone, 5% azone and 33% coconut oil (all %/w/v).

25

- 10 -

**Example 4****Gel composition.**

5 Further gels in accordance with the invention can be prepared using the following materials in the proportions set out below:

	% w/w
cis-UCA	0.1-10
10 Sodium carboxymethyl cellulose	1.5-2.5
Sorbic acid	0.75
Propylene glycol	2.0-25
Buffering agent	0.01-1
15 Purified Water	to 100

The preferred composition for such a gel is 5% cis-UCA, 2% sodium carboxymethyl cellulose, 0.75% sorbic acid 10% propylene glycol, 0.1% buffering agent and purified  
20 water to 100% (all %w/w).

**Example 5****Cream Composition.**

25

Creams in accordance with the invention can be prepared

- 11 -

using the following materials in the proportions set out below:

	cis-UCA	0.1-10
	Cosmowax	10-25
5	Oleyl Alcohol	0.1-10
	Oleic Acid	0.1-10
	Liquid Paraffin	5-25
	Polysorbate 20	0.1-5
	Phenonip	0.1-1
10	Buffering Agent	0.01-1
	Sorbic Acid	0.075
	Purified Water	to 100

The preferred composition for such a cream is 5% cis-  
15 UCA, 15% cosmowax, 3% oleyl alcohol, 2% oleic acid, 15%  
liquid paraffin, 1% polysorbate 20, 0.5% phenonip, 0.1%  
buffering agent, 0.075% sorbic acid and water to 100%.

#### Example 6

20

#### Paint Composition.

Paints in accordance with the invention can be prepared  
using the following materials in the proportions set out  
25 below:

		% w/v
cis-UCA		0.1-10
Purified Water		0-60
Dimethyl Sulphoxide	To	100


5

The preferred composition for such a paint is 5% cis-UCA, 20% purified water and 75% dimethyl sulphoxide.

CLAIMS

1. A compound of general formula I:-

5



wherein Q is a substituted or unsubstituted furanyl, imidazolyl, pyrrolyl or thiopheneyl group, R is  $CR^1-CR^2$ , (cis) $CR^1=CR^2$ , or (trans)- $CR^1=CR^2$ , X is  $COOR^3$  or  $NR^1R^4$ , and  $R^1-R^4$  are each, independently, H, or an alkyl or an aryl group, or a pharmaceutically acceptable salt thereof, for use in a topical treatment of a skin condition which involves an overactive immune response, or which is responsive to UV irradiation.

15 2. A compound as claimed in claim 1, wherein Q is unsubstituted, or substituted with F, Cl, Br or  $CH_3$ .

3. A compound as claimed in claim 1 or claim 2, wherein  $R^1-R^4$  each, independently, are H, a lower alkyl group or a phenyl group.

4. A compound as claimed in any of claims 1-3, wherein R is (cis)  $CR^1 = CR^2$ .

25 5. A compound as claimed in any of claims 2-4, wherein Q is unsubstituted.

6. A compound as claimed in any of claims 2-5, wherein R<sup>1</sup>-R<sup>4</sup> are each H.

7. Cis-urocanic acid, or a pharmaceutically acceptable salt thereof, for use in a topical treatment of a skin condition which involves an over active immune response, or which is responsive to UV radiation.

8. Trans-urocanic acid, or a pharmaceutically acceptable salt thereof, for use in a topical treatment of a skin condition which involves an over active immune response, or which is responsive to UV radiation, which treatment comprises irradiating said compound with UV, after topical application thereof, to convert at least a proportion of the trans-urocanic acid into cis-urocanic acid.

9. A compound, as claimed in any of the preceding claims, wherein the skin condition is a photodermatosis, such as polymorphic light eruption, photosensitivity, dermatitis/ actinic reticuloid syndrome, actinic purrigo or solar urticaria; a general urticaria of an allergic or a non-allergic type; acne vulgaris, alopecia areata, dermatitis herpetiformis, eosinophilic pustular folliculitis, erythrokeratoderma (symmetrical and progressive), chronic lichenoid GVH disease, granuloma annulare, histiocytosis X, ichthyosis linearis circumflexa, lichen planus,



pityriasis lichenoides, pityriasis rosea, pityriasis  
rubra pilaris, pressure sores, pruritis (primary and  
secondary), scleromyxoedema, subcorneal pustular  
dermatoses, transient acantholytic dermatoses,  
5 psoriasis or atopic eczema.

10. A pharmaceutical composition comprising a compound of  
general formula I, as defined in any of claims 1-7, in  
admixture with a pharmaceutically acceptable excipient or  
10 carrier and suitable for topical use.

11. A pharmaceutical composition as claimed in claim 10,  
for use in a topical treatment of a skin condition which  
involves an over active immune response or which is  
15 responsive to UV radiation.

12. A pharmaceutical composition, as claimed in claim 11,  
wherein the compound of general formula I is trans-urocanic  
acid and the treatment comprises irradiating the composition  
20 with UV light after topical application thereof, to convert  
at least a proportion of the trans-urocanic acid into cis-  
urocanic acid.

13. A pharmaceutical composition, as claimed in any of  
25 claims 10-12, wherein the skin condition is a  
photodermatitis, such as polymorphic light eruption,

photosensitivity, dermatitis/actinic reticuloid syndrome, actinic purrigo or solar urticaria; a general urticaria of an allergic or a non-allergic type; acne vulgaris, alopecia areata, dermatitis herpetiformis, eosinophilic pustular  
5 folliculitis, erythrokeratoderma (symmetrical and progressive), chronic lichenoid GVH disease, granuloma annulare, histiocytosis X, ichthyosis linearis circumflexa, lichen planus, pityriasis lichenoides, pityriasis rosea, pityriasis rubra pilaris, pressure sores, pruritis (primary  
10 and secondary), scleromyxoedema, subcorneal pustular dermatoses, transient acantholytic dermatoses, psoriasis or atopic eczema.

14. A pharmaceutical composition, as claimed in any of  
15 claims 10-13, comprising an ointment, gel, aerosol, wipe, cream, lotion or emulsion.

15. Use of a compound of general formula I, as defined in any of claims 1-7, for the manufacture of a medicament for  
20 use in a method of topically treating a skin condition which involves an over active immune response, or which is responsive to UV irradiation.

16. A use, as claimed in claim 15, wherein the compound is  
25 trans-urocanic acid and the method further comprises irradiating said compound with UV after topical application

thereof, to convert at least a proportion of the trans-urocanic acid into cis-urocanic.

17. A use, as claimed in either of claims 15 or 16, wherein  
5 the skin condition is a photodermatosis, such as polymorphic light eruption, photosensitivity, dermatitis/actinic reticuloid syndrome, actinic purrigo or solar urticaria; a general urticaria of an allergic or a non-allergic type; acne vulgaris, alopecia areata, dermatitis herpetiformis,  
10 eosinophilic pustular folliculitis, erythrokeratoderma (symmetrical and progressive), chronic lichenoid GVH disease, granuloma annulare, histiocytosis X, ichthyosis linearis circumflexa, lichen planus, pityriasis lichenoides, pityriasis rosea, pityriasis  
15 rubra pilaris, pressure sores, pruritis (primary and secondary), seleromyxoedema, subcorneal pustular dermatoses, transient acantholytic dermatoses, psoriasis or atopic eczema.

20 18. A use, as claimed in any of claims 15-17, wherein the medicament includes a pharmaceutically acceptable excipient or carrier and is suitable for topical use.

19. A use, as claimed in any of claims 15-18, wherein the  
25 medicament is an ointment, gel, aerosol, wipe, cream, lotion or emulsion.

20. A method of treating a skin condition which involves an over active immune response, or which is responsive to UV irradiation, comprising topically applying a compound as  
5 claimed in any of claims 1-7, or a pharmaceutical composition as claimed in claim 10.

21. A method as claimed in claim 20, wherein the composition or compound includes trans-urocanic acid and,  
10 after topical application thereof, said compound or composition is irradiated with UV, to convert at least a proportion of the trans-urocanic acid into cis-urocanic acid.

15 22. A method as claimed in any of claims 20-21, wherein the skin condition is a photodermatosis, such as polymorphic light eruption, photosensitivity, dermatitis/actinic reticuloid syndrome, actinic prurigo or solar urticaria; a general urticaria of an allergic or a non-allergic type;  
20 acne vulgaris, alopecia areata, dermatitis herpetiformis, eosinophilic pustular folliculitis, erythrokeratoderma (symmetrical and progressive), chronic lichenoid GVH disease, granuloma annulare, histiocytosis X, ichthyosis linearis circumflexa, lichen planus,  
25 pityriasis lichenoides, pityriasis rosea, pityriasis rubra pilaris, pressure sores, pruritis (primary and

secondary), seleromyxoedema, subcorneal pustular  
dermatoses, transient acantholytic dermatoses,  
psoriasis or atopic eczema.

**This Page Blank (uspto)**



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> : <b>A61K 31/415</b>	<b>A3</b>	(11) International Publication Number: <b>WO 94/22441</b> (43) International Publication Date: <b>13 October 1994 (13.10.94)</b>
<p>(21) International Application Number: <b>PCT/GB94/00650</b></p> <p>(22) International Filing Date: <b>29 March 1994 (29.03.94)</b></p> <p>(30) Priority Data: <b>9306473.1</b>      <b>29 March 1993 (29.03.93)</b>      <b>GB</b></p> <p>(71) Applicant (for all designated States except US): <b>BIOGLAN IRELAND (R &amp; D) LIMITED [IE/IE]; Unit 5, 151 Baldoyle Industrial Estate, Dublin 13 (IE).</b></p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): <b>GOODMAN, Michael [GB/GB]; 27 Barley Rise, Baldock, Hertfordshire SG7 6RT (GB). FERGUSON, James [GB/GB]; Dept. of Dermatology, Ninewells Hospital, Dundee DD1 9SY (GB).</b></p> <p>(74) Agent: <b>JUMP, Timothy, John, Simon; Venner, Shipley &amp; Co., 20 Little Britain, London EC1A 7DH (GB).</b></p>	<p>(81) Designated States: <b>AU, BB, BG, BR, BY, CA, CN, CZ, FL, GB, HU, JP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</b></p> <p><b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p>(88) Date of publication of the international search report: <b>24 November 1994 (24.11.94)</b></p>	
<p>(54) Title: <b>USE OF CIS- OR TRANSUROCANIC ACID FOR THE TREATMENT OF PHOTODERMATOSES AND IMMUNOGENIC SKIN DISEASES</b></p> <p>(57) Abstract</p> <p>A compound of the general formula (I): Q-R-X wherein Q is a substituted or unsubstituted furanyl, imidazolyl, pyrrolyl or thiophenyl group, R is CR<sup>1</sup><sub>2</sub>-CR<sup>2</sup><sub>2</sub>, (cis)-CR<sup>1</sup> = CR<sup>2</sup>, or (trans)-CR<sup>1</sup> = CR<sup>2</sup>, X is COOR<sup>3</sup> or NR<sup>1</sup>R<sup>4</sup>, and R<sup>1</sup>-R<sup>4</sup> are each, independently, H, an alkyl or an aryl group and pharmaceutically acceptable salts thereof, are described for use in topical treatments of skin conditions which involve an overactive immune response, or which are responsive to UV irradiation. Pharmaceutical compositions of the compound of general formula (I) are also described.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TC	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				



## INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/GB 94/00650

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 5 A61K31/415

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 5 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE,A,41 22 497 (OPTIMUM PATENTWERTUNGSGESELLSCHAFT MBH) 21 January 1993 see the whole document especially column 1, line 8-9 ---	1-22
X	EP,A,0 467 116 (BODE CHEMIE GMBH & CO.) 22 January 1992 see the whole document especially page 2, line 48-49 & page 3, line 18 ---	1-22
X	DE,A,10 03 922 (P. BEIERSDORF & CO. A.-G.) 7 March 1957  see the whole document ---	1-6, 9-11, 13-15

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*I\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

11 July 1994

Date of mailing of the international search report

21. 10. 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

MAIR J.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 94/00650

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DE,A,12 35 506 (VEB ARZNEIMITTELWERK DRESDEN) 2 March 1967</p> <p>see the whole document -----</p>	<p>1-6, 9-11, 13-15</p>

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB94/00650

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
**REMARK: Although claims 20-22 are directed towards a method of treatment of the human or animal body the search has been carried out and based on the alleged effects of the compositions.**
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

For further information please see annex.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

## CONTINUATION OF BOX II:

To search this plurality of different subjects would have required "major additional searching efforts".

The application has been divided into the following subjects:

1. Claims: 1-6, 9-11, 13-15, 17-20, 22 (partially). Compounds of formula I wherein Q is substituted or unsubstituted furanyl and their use for the treatment of abovementioned skin diseases.
  2. Claims: 1-6, 9-11, 13-15, 17-20, 22 (partially) & 7, 8, 12, 16, 21. Compounds of formula I wherein Q is substituted or unsubstituted imidazolyl and their use for the treatment of abovementioned skin diseases.
  3. Claims: 1-6, 9-11, 13-15, 17-20, 22 (partially). Compounds of formula I wherein Q is substituted or unsubstituted pyrrolyl and their use for the treatment of abovementioned skin diseases.
  4. Claims: 1-6, 9-11, 13-15, 17-20, 22 (partially). Compounds of formula I wherein Q is substituted or unsubstituted thiophenyl and their use for the treatment of abovementioned skin diseases.
- Only the first subject has been fully searched. Attention is also drawn to the abovementioned documents, namely DE-A-4122497 and EP-A-467116, in connection with the novelty of subject 2.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 94/00650

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE-A-4122497	21-01-93	NONE	
EP-A-0467116	22-01-92	DE-A- 4121030 JP-A- 4230321	02-01-92 19-08-92
DE-A-1003922		NONE	
DE-A-1235506		NONE	

**This Page Blank (uspto)**